Limast Dosage/Direction for Use

Tacrolimus Capsule therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.
Inadvertent, unintentional or unsupervised switching of immediate- or prolonged release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist. Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.
General considerations: The recommended initial dosages presented as follows are intended to act solely as a guideline. Tacrolimus Capsule dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see as follows for recommended target whole blood trough concentrations). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered.
Tacrolimus Capsule can be administered orally. In general, dosing may commence orally; if necessary, by administering the capsule contents suspended in water, via nasogastric tubing.
Tacrolimus Capsule is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period. The Tacrolimus Capsule dose may vary depending upon the immunosuppressive regimen chosen.
Posology: Dosage recommendations: Liver transplantation Prophylaxis of transplant rejection: Adults: Oral Tacrolimus Capsule therapy should commence at 0.10-0.20 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence approximately 12 hours after the completion of surgery.
Prophylaxis of transplant rejection: Children: An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening).
Dose adjustment during post-transplant period in adults and children: Tacrolimus Capsule doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Tacrolimus Capsule monotherapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.
Rejection therapy: Adults and children: Increased Tacrolimus Capsule doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions, see Adverse Reactions) the dose of Tacrolimus Capsule may need to be reduced. For conversion to Tacrolimus Capsule, treatment should begin with the initial oral dose recommended for primary immunosuppression.
For information on conversion from ciclosporin to Tacrolimus Capsule, see as follows under "Dose adjustments in specific patient populations".
Dosage recommendations: Kidney transplantation: Prophylaxis of transplant rejection: Adults: Oral Tacrolimus Capsule therapy should commence at 0.20-0.30 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 24 hours after the completion of surgery.
If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.05-0.10 mg/kg/day should be initiated as a continuous 24-hour infusion.
Prophylaxis of transplant rejection: Children: An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.075-0.100 mg/kg/day should be administered as a continuous 24-hour infusion.
Dose adjustment during post-transplant period in adults and children: Tacrolimus Capsule doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Tacrolimus Capsule-based dual-therapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.
Rejection therapy: Adults and children: Increased Tacrolimus Capsule doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions, see Adverse Reactions) the dose of Tacrolimus Capsule may need to be reduced. For conversion to Tacrolimus Capsule, treatment should begin with the initial oral dose recommended for primary immunosuppression.
For information on conversion from ciclosporin to Tacrolimus Capsule, see as follows under "Dose adjustments in specific patient populations".
Dosage recommendations: Heart transplantation: Prophylaxis of transplant rejection: Adults: Tacrolimus Capsule can be used with antibody induction (allowing for delayed start of Tacrolimus Capsule therapy) or alternatively in clinically stable patients without antibody induction.
Following antibody induction, oral Tacrolimus Capsule therapy should commence at a dose of 0.075 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 5 days after the completion of surgery as soon as the patient's clinical condition is stabilised. If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 to 0.02 mg/kg/day should be initiated as a continuous 24-hour infusion.
An alternative strategy was published where oral tacrolimus was administered within 12 hours post transplantation. This approach was reserved for patients without organ dysfunction (e.g. renal dysfunction). In that case, an initial oral tacrolimus dose of 2 to 4 mg per day was used in combination with mycophenolate mofetil and corticosteroids or in combination with sirolimus and corticosteroids.
Prophylaxis of transplant rejection: Children: Tacrolimus Capsule has been used with or without antibody induction in paediatric heart transplantation.
In patients without antibody induction, if Tacrolimus therapy is initiated intravenously, the recommended starting dose is 0.03-0.05 mg/kg/day as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15-25 ng/mL. Patients should be converted to oral therapy as soon as clinically practicable. The first dose of oral therapy should be 0.30 mg/kg/day starting 8 to 12 hours after discontinuing intravenous therapy.
Following antibody induction, if Tacrolimus Capsule therapy is initiated orally, the recommended starting dose is 0.10-0.30 mg/kg/day administered as two divided doses (e.g. morning and evening).
Dose adjustment during post-transplant period in adults and children: Tacrolimus Capsule doses are usually reduced in the post-transplant period. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.
Rejection therapy: Adults and children: Increased Tacrolimus Capsule doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.
In adult patients converted to Tacrolimus Capsule, an initial oral dose of 0.15 mg/kg/day should be administered in two divided doses (e.g. morning and evening). In paediatric patients converted to Tacrolimus Capsule, an initial oral dose of 0.20-0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening).
For information on conversion from ciclosporin to Tacrolimus Capsule, see as follows under "Dose adjustments in specific patient populations".
Dosage recommendations: Rejection therapy, other allografts: The dose recommendations for lung, pancreas and intestinal transplantation are based on limited prospective clinical trial data. In lung-transplanted patients Tacrolimus Capsule has been used at an initial oral dose of 0.10-0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day.
Dosage adjustments in specific patient populations: Patients with liver impairment: Dose reduction may be necessary in patients with severe liver impairment in order to maintain the blood trough levels within the recommended target range.
Patients with kidney impairment: As the pharmacokinetics of tacrolimus are unaffected by renal function, no dose adjustment should be required. However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).
Paediatric population: In general, paediatric patients require doses 1½ - 2 times higher than the adult doses to achieve similar blood levels.
Older people: There is no evidence currently available to indicate that dosing should be adjusted in older people.
Conversion from ciclosporin: Care should be taken when converting patients from ciclosporin-based to Tacrolimus Capsule-based therapy. Tacrolimus Capsule therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated ciclosporin blood levels. In practice, Tacrolimus Capsule therapy has been initiated 12-24 hours after discontinuation of ciclosporin. Monitoring of ciclosporin blood levels should be continued following conversion as the clearance of ciclosporin might be affected.
Target whole blood trough concentration recommendations: Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient.
As an aid to optimise dosing, several immunoassays are available for determining tacrolimus concentrations in whole blood including a semi-automated microparticle enzyme immunoassay (MEIA). Comparisons of concentrations from the published literature to individual values in clinical practice should be assessed with care and knowledge of the assay methods employed. In current clinical practice, whole blood levels are monitored using immunoassay methods.
Blood trough levels of tacrolimus should be monitored during the post-transplantation period. When dosed orally, blood trough levels should be drawn approximately 12 hours post-dosing, just prior to the next dose. The frequency of blood level monitoring should be based on clinical needs. As Tacrolimus Capsule is a medicinal product with low clearance, adjustments to the dosage regimen may take several days before changes in blood levels are apparent. Blood trough levels should be monitored approximately twice weekly during the early post-transplant period and then periodically during maintenance therapy. Blood trough levels of tacrolimus should also be monitored following dose adjustment, changes in the immunosuppressive regimen, or following co-administration of substances which may alter tacrolimus whole blood concentrations.
Clinical study analysis suggests that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/mL. It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.
In clinical practice, whole blood trough levels have generally been in the range 5-20 ng/mL in liver transplant recipients and 10-20 ng/mL in kidney and heart transplant patients in the early post-transplant period. Subsequently, during maintenance therapy, blood concentrations have generally been in the range of 5-15 ng/mL in liver, kidney and heart transplant recipients.
Method of administration: It is recommended that the oral daily dose be administered in two divided doses (e.g. morning and evening). Capsule should be taken immediately following removal from the blister. Patients should be advised not to swallow the desiccant. The capsule should be swallowed with fluid (preferably water).
Capsule should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.
Duration of dosing: To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.